CA2291449A1 - In vivo modification of galactomannans in guar by expression of udp-galactose epimerase antisense rna - Google Patents
In vivo modification of galactomannans in guar by expression of udp-galactose epimerase antisense rna Download PDFInfo
- Publication number
- CA2291449A1 CA2291449A1 CA002291449A CA2291449A CA2291449A1 CA 2291449 A1 CA2291449 A1 CA 2291449A1 CA 002291449 A CA002291449 A CA 002291449A CA 2291449 A CA2291449 A CA 2291449A CA 2291449 A1 CA2291449 A1 CA 2291449A1
- Authority
- CA
- Canada
- Prior art keywords
- galactose
- mannose
- containing compound
- nucleotide sequence
- udp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8245—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
Abstract
An in vivo modification process is described. The process affects the mannoseto-galactose ratio of either an organism (or part thereof) capable of producing a mannose/galactose containing compound or of a mannose/galactose containing compound thereof. The in vivo modification process comprises expressing a nucleotide sequence that has an effect on: (a) the mannose-to-galactose ratio of mannose and galactose components of a mannose/galactose containing compound; and/or (b) the mannose-to-galactose ratio of mannose and galactose precursors for a mannose/galactose containing compound; and wherein the nucleotide sequence is antisense to at least a part of the gene for a UDPgalactose epimerase enzyme.
Description
IN VIVO MODIFICATION OF GALACTOMANNANS IN GUAR BY EXPRESSION OF UDP-GALACTOSE
EPIMERASE
ANTISENSE RNA
The present invention relates to a modification process.
In particular, the present invention relates to an in vivo modification process.
Galactomannans are a heterogenous group of cell wall polysaccharides consisting of a ~3-1-4 linked mannan backbone with varying numbers of a-1-6 linked galactose side chains.
The galactomannans of most significant industrial use are obtained from the endosperms of the legumes g<.Iar (Cyamopsis tetragonolobus) and locust bean (Ceratonia siliqua). These galactomannans differ in their galactose content, with guar having a galactose to mannose ratio of approximately 1:1.6, whereas the ratio for locust bean gum (LBG) is approximately 1:3.4.
The differences in galactose content have significant effects on the functional properties of guar gum and LBG. Both galactomannans form highly viscous solutions at low concentrations (1-2%) but LBG has the additional property of being able to form firm gels with other polysaccharides such as xanthan, carrageenan and agarose. LBG is extensively used by the food industry in dairy products (notably ice cream), salad dressings, sauces, low calorie products and pet foods. However, the use of LBG is restricted by the high price and irregular supply.
Therefore, large scale production of galactomannans with improved functional properties, such as a result of an increased mannose to galactose ratio (such as that similar to LBG), is desirable.
Due to the generic chemical similarity between guar gum and LBG and the much lower price on guar gum, it has been attempted in vitro to convert guar gum into a galactomannan with LBG-like properties and with a chemical composition similar to LBG.
SUBSTITUTE SHEET (RULE 26) An example of such an in vitro treatment includes the use of a-galactosidase.
In this regard, see McCleary et al 1983 and EP-A-0255153.
By using a-galactosidase purified from guar seeds, guar gum with galactose contents of 10-34% was obtained (Bulpin et al 1990). Analysis of the gelation behaviour of the modified guar gum showed that a preparation with a galactose content of 24 %
formed mixed gels with carrageenan displaying similar rheological properties as LBG.
In comparison, the galactose content of untreated guar gum was 38 % and 23 % for LBG.
However, from an industrial point of view in vitro degalactosylation of guar gum is associated with a number of problems.
First, huge amounts of a-galactosidase have to be prepared as about 40% of the galactose in the guar gum has to be removed.
Second, during incubation it is very important that no hydrolysis of the mannan backbone occurs necessitating the use of highly purified a-galactosidase preparations devoid of any trace of mannanase activity. A procedure for heterologous production of the a-galactosidase from guar seed has been published (Overbeeke et al 1986).
However, the produced a-galactosidases from the tested species were purified before investigating the action on guar gum suggesting that the mannanase problem remains to be solved.
Third, the yield of galactomannan is reduced because a 40% reduction in galactose content corresponds to approximately 15 % less modified guar gum. The released galactose may be undesirable in the final product and may have to be removed.
Fourth, there is a considerable risk for depolymerisation of the galactomannan during incubation with a-galactosidase.
SUBSTITUTE SHEET (RULE ~.~ ) Also, there is a risk for contaminating microorganisms to colonise the reaction mixture releasing endo-~i-mannanases.
Finally, water has to be removed from the reaction mixture. In addition to the cost of this process, it will also result in concentration of the buffer that may be used for obtaining optimal reaction conditions.
These examples demonstrate that the present methods for the modification of guar gum are associated with problems, some of which are associated with considerable costs.
There is therefore a need to have an improved method for the modification of guar gum.
In this regard, we have already proposed the modification of a mannose/galactose containing compound (such as guar gum) wherein the modification occurs in vivo in plants, such as guar plants, and by use of recombinant DNA techniques. In particular, we refer to PCT/EP96/05581 which was filed 2 December 1996 (the contents of which are incorporated herein by reference).
In its broadest sense, PCTIEP96/05581 relates to in vivo modification of a mannose/galactose containing compound - such as guar gum - in an organism (or part thereof) capable of synthesising that compound by a method that is not native to that organism - such as by a method that makes use of recombinant DNA techniques.
The modification may occur in relation to any one or more of the precursors of the compound (e.g. mannose and/or galactose) or in relation to the compound itself (i.e.
modification of the mannose and/or galactose units of a compound comprising same).
In particular, PCT/EP96/05581 relates to an in vivo modification process that affects, preferably increases, the mannose-to-galactose ratio of either an organism (or part thereof) capable of producing a mannose/galactose containing compound or of a mannoselgalactose containing compound thereof. This in vivo modification process is not a naturally occurring process.
SUBSTITUTE SHEET (RULE 26) Thus, with the in vivo process of PCT/EP96/05581, it is possible to alter the internal in vivo ratio of mannose to galactose within an organism and/or the ratio of mannose to galactose of a mannose/galactose compound thereof.
One of the requirements for the production of in vivo modified guar gum is the availability of a method for the introduction of suitable genes into guar. This has been accomplished to a limited extent by J~rsboe and Okkels (1994) who transferred a selectable and screenable gene used for the development of the transformation method. These authors did not report on transformation with a gene to affect the mannose to galactose ratio. This is an important point as, from a biotechnological point of view, the major obstacle for the production of in vivo modified guar gum is the lack of knowledge of galactomannan biosynthesis. Up until now, no genes or gene products which control the biosynthesis of guar gum in vivo have been isolated and characterised. However, in PCTIEP96/05581 we 1 ~ determined some of the genes or gene products which control the biosynthesis of guar gum in vivo - thus enabling us to modify guar gum in vivo.
We now provide a new process for the modification of a mannose/galactose containing compound (such as guar gum).
According to a first aspect of the present invention we provide an in vivo modification process that affects the mannose-to-galactose ratio of either an organism (or part thereof) capable of producing a mannose/galactose containing compound or of a mannose/galactose containing compound thereof, wherein the in vivo modification process comprises expressing a nucleotide sequence that has an effect on: (a) the mannose-to-galactose ratio of mannose and galactose components of a mannoselgalactose containing compound;
and/or (b) the mannose-to-galactose ratio of mannose and galactose precursors for a mannoselgalactose containing compound; and wherein the nucleotide sequence is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme.
SUBSTITUTE ShIEET (RULE 26) According to a second aspect of the present invention we provide the use of a nucleotide sequence to affect in vivo the mannose-to-galactose ratio of either an organism (or part thereof) capable of producing a mannose/galactose containing compound or of a mannose/galactose containing compound thereof, wherein the nucleotide sequence is 5 antisense to at least a part of the gene for a UDP-galactose epimerase enzyme, and wherein the nucleotide sequence has an effect on: (a) the mannose-to-galactose ratio of mannose and galactose components of a mannose/galactose containing compound;
and/or (b) the mannose-to-galactose ratio of mannose and galactose precursors for a mannose/galactose containing compound.
In a preferred embodiment, the nucleotide sequence is antisense to at least a pan of the coding sequence for a UDP-galactose epimerase enzyme.
The term "mannose/galactose containing compound" means a compound comprising at least one mannose group and at least one galactose group.
It is preferred that the mannose/galactose containing compound is gaiactomannan.
It is more preferred that the mannose/galactose containing compound is guar gum.
It is more preferred that the organism capable of producing a mannose/galactose containing compound is a guar plant and the mannose/galactose containing compound thereof is galactomannan. However, other galactomannan producing plants are encompassed such as fenugreek and Lucerne. Plants that are considered not to produce appropriate quantities of galactomannan belong to the family Solanacea and the species Nicotiana tabacum.
The term "organism (or part thereof) capable of producing a mannose/galactose containing compound" also includes any suitable organism - in particular a plant -capable of producing a mannose/galactose containing compound, such that the internal in vivo ratio of mannose to galactose of that organism is altered. The term also includes any part of an SUBSTITUTE SHEET (RULE 26) organism that is capable of producing a mannose/galactose containing compound, such that the ratio of mannose to galactose of that part is altered. The term also includes a pan when within an organism or in a live culture medium. Preferably, the part is when within an organism per se. An example of a part is seed.
The term "mannose and galactose precursors" includes mannose per se or derivatives thereof and/or galactose per se or derivatives thereof as precursors for the biosynthesis of a mannose/galactose containing compound, preferably galactomannan. In addition, the term includes precursors for mannose per se or derivatives thereof and/or galactose per se or derivatives thereof which in turn are used as precursors for the biosynthesis of a mannose/galactose containing compound, preferably galactomannan. Preferably, the term means mannose per se or derivatives thereof (such as mannose-6-phosphate or GDP-mannose) and/or galactose per se or derivatives thereof as precursors for the biosynthesis of galactomannan, preferably guar galactomannan.
Preferably the in vivo mannose-to-galactose ratio of the organism (or part thereof) or mannose/gaiactose containing compound thereof is higher than that of the guar plant or the galactomannan thereof.
More preferably the in vivo mannose-to-galactose ratio of the organism (or part thereof or mannose/galactose containing compound thereof is substantially similar to that of the locust bean or the galactomarman thereof.
Preferably the organism (or part thereof) or mannose/galactose containing compound thereof is a guar plant or the gum thereof.
The present invention also covers a mannose/galactose containing compound when prepared by the process of the present invention. This mannose/galactose containing compound will be referred to as a mannose/galactose containing compound according to the present invention.
SUBSTITUTE SHEET (RULE 26) In addition, the present invention also covers a foodstuff comprising a mannose/galactose containing compound according to the present invention.
In addition, the present invention also covers a composition - such as a foodstuff -comprising a mannose/galactose containing compound according to the present invention admixed with another polysaccharide. Preferably that other saccharide is any one or more of xanthan, carrageenan and agarose.
In addition, the present invention covers methods for preparing compositions or foodstuffs according to the present invention comprising mixing the mannose/galactose containing compound according to the present invention with another suitable ingredient.
The broad aspects of the present invention can be achieved by the use of a nucleotide sequence that is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme. UDP-galactose epimerase enzyme converts UDP-glucose to UDP-galactose which is incorporated into the galactomannan. With this strategy, expression of antisense UDP-galactose epimerase reduces the epimerase activity and thereby increases the in vivo mannose-to-galactose ratio of mannose and galactose precursors for the biosynthesis of a mannose containing compound, such as galactomannan.
A preferred aspect of the present invention relates to a construct comprising or expressing the nucleotide sequence of the present invention.
Another preferred aspect of the present invention relates to a vector comprising or expressing the construct or nucleotide sequence of the present invention.
Another preferred aspect of the present invention relates to a plasmid comprising or expressing the vector, constn:ct or nucleotide sequence of the present invention.
SUBSTITUTE SHEET (RULE 26) Another preferred aspect of the present invention relates to a transgenic organism comprising or expressing the plasmid, vector, construct or nucleotide sequence of the present invention.
Other preferred aspects of the present invention include methods of expressing or allowing expression or transforming anyone of the nucleotide sequence, the construct, the plasmid, the vector, the cell, the tissue, the organ or the organism, as well as the products thereof.
Further preferred aspects of the present invention include uses of the antisense nucleotide sequence according to the present invention for preparing or treating foodstuffs, including animal feed.
One of the key advantages of the present invention is that by using the anti-sense sequence it is possible to increase the mannose-to-galactose ratio of organisms or mannose containing compounds thereof, in particular in vivo modified guar gum.
The antisense nucleotide sequence may be used in vivo in combination with one or more other nucleotide sequences, which nucleotide sequences are preferably prepared by use of recombinant DNA techniques.
Likewise the nucleotide sequence of the present invention may be used in combination with one or more gene products to further affect the mannose-to-galactose ratio, which gene products are preferably prepared by use of recombinant DNA techniques.
Here, the gene products can be any one or more of peptides, polypeptides, proteins, enzymes and RNA. Preferably, at least one of the gene products is an enzyme that is expressed by a nucleotide sequence that is not a natural nucleotide sequence. Here, the term "a natural nucleotide sequence" means an entire nucleotide sequence that is in its natural environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its natural environment.
SU6STITUTE SHEET (RULE 26) By way of example, in some instances it is preferred that the antisense nucleotide sequence according to the present invention is used in conjunction with one or more genes encoding enzymes that are required for the biosynthesis of GDP-mannose - namely the enzyme phosphomannose isomerase (PMI) and/or the enzyme phosphomannose mucase and/or the enzyme GDP-mannose pyrophosphorylase - and/or with one or more genes encoding an a-galactosidase.
In a more preferred instance the nucleotide sequence according to the present invention is used in conjunction with a gene encoding the enzyme phosphomannose isomerase (PMI) and/or with a Gene encoding an a-aalactosidase. A preferred PMI and a-galactosidase are disclosed and discussed in PCTlEP96/0558I (the contents of which are incorporated herein by reference).
The present invention also encompasses the use of variants, homologues or fragments of the nucleotide sequence according to the present invention. Here the terms "variant" , "homologue" or "fragment" in relation to the nucleotide sequence include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence is similar to a nucleotide sequence that is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme and wherein the resultant nucleotide sequence is capable of affecting the mannose-to-galactose ratio as defined above. These terms are synonymous with allelic variations of the sequences.
The UDP-galactose epimerase enzyme - the gene sequence of which the nucleotide sequence of the present invention is antisense to - may be any suitable UDP-galactose epimerase enzyme. Preferably the UDP-galactose epimerase enzyme - the gene sequence of which the nucleotide sequence of the present invention is antisense to - is an endogenous UDP-galactose epimerase enzyme or an enzyme having a sequence similar thereto (such as at least 85 % sequence similarity, preferably at least 90%
sequence similarity, more preferably at least 95 % sequence similarity, more preferably at least 98 sequence similarity).
SUBSTITUTE SHEET (RULE 26) In accordance with a preferred embodiment of the present invention the UDP-galactose epimerase enzyme - the gene sequence of which the nucleotide sequence of the present invention is antisense to - may be or may comprise the amino acid sequence as presented in SEQ ID No. 1 or SEQ ID No. 2, or a variant, homologue or fragment thereof.
In accordance with a more preferred embodiment of the present invention the UDP-galactose epimerase enzyme - the gene sequence of which the nucleotide sequence of the present invention is antisense to - may be or may comprise the amino acid sequence as presented in SEQ ID No. 1 or SEQ ID No. 2.
In addition, and according to a further preferred embodiment of the present invention the nucleotide sequence of the present invention is antisense to the UDP-galactose epimerase enzyme coding sequence that is presented in SEQ ID No. 1 or SEQ ID No. 2, or a variant, homologue or fragment thereof.
According to a further preferred embodiment of the present invention the nucleotide sequence of the present invention is antisense to the UDP-galactose epimerase enzyme coding sequence that is presented in SEQ ID No. 1 or SEQ iD No. 2.
As indicated above, the terms "variant" , "homologue" or "fragment" in relation to the amino acid sequence for the preferred UDP-gaiactose epimerase enzyme vis-a-vis the antisense nucleotide sequence of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant enzyme has UDP-galactose epimerase activity, preferably having at least the same activity of the enzyme comprising the sequence shown as SEQ ID No. 1 or SEQ ID No. 2. In particular, the term "homologue"
covers homology with respect to structure and/or function. With respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90%o homology to an enzyme comprising the sequence shown as SEQ ID
No. 1 or SEQ ID No. ? . More preferably there is at least 95 % , more preferably at least 98 % , SUBSTITUTE SHEET (RULE 28) homology to an enzyme comprising the sequence shown as SEQ ID No. 1 or SEQ ID
No.
2.
The terms "variant", "homologue" or "fragment'' in relation to the nucleotide sequence coding for the UDP-galactose epimerase enzyme vis-a-vis the antisense nucleotide sequence of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence codes for or is capable of coding for an enzyme having UDP-galactose epimerase activity, preferably having at least the same activity of the enzyme comprising the sequence shown as SEQ ID No. 1 or SEQ ID
No.
2. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence codes for or is capable of coding for an enzyme having UDP-galactose epimerase activity. With respect to sequence homology, preferably there is at least 75 % , more preferably at least 85 % , more preferably at least 90% homology to a sequence comprising the sequence shown as SEQ ID No. 1 or SEQ
ID No. 2. More preferably there is at least 95%, more preferably at least 98%, homology to a sequence that comprises the sequence shown as SEQ ID No. 1 or SEQ ID No.
2.
The terms "variant" , "homologue" or "fragment" in relation to the antisense nucleotide sequence according to the present invention - namely a sequence that is antisense to that coding for the UDP-galactose epimerase enzyme - include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence is antisense to a sequence that codes for or is capable of coding for an enzyme having UDP-galactose epimerase activity, preferably having at least the same activity of the enzyme comprising the sequence shown as SEQ ID No. 1 or SEQ ID No. 2. In particular, the term "homologue"
covers homology with respect to structure and/or function providing the resultant nucleotide sequence is antisense to a sequence that codes for or is capable of coding for an enzyme having UDP-galactose epimerase activity. With respect to sequence homology, preferably there is at least 75 % , more preferably at least 85 % , more preferably at least 90% homology to a sequence comprising a sequence that is antisense to the sequence shown as SEQ ID No. 1 or SEQ ID No. 2. More preferably there is at least 95 %
, more SUBSTITUTE SHEET (RULE 26) preferably at least 98 % , homology to a sequence comprising a sequence that is antisense to the sequence shown as SEQ ID No. 1 or SEQ ID No. 2.
The transgenic organism of the present invention includes an organism comprising any one or more of the nucleotide sequences according to the present invention, constructs according to the present invention, vectors according to the present invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention, or the products thereof, including combinations thereof. For example the transgenic organism can also comprise any one or more of the nucleotide sequences of the present invention under the control of one or more heterologous promoters.
In a highly preferred embodiment, the transgenic organism (or part thereof) does not comprise the combination of a promoter and the nucleotide sequence according to the present invention, wherein both the promoter and the nucleotide sequence are native to that organism (or pan thereof] and are in their natural environment.
The term "promoter" is used in the normal sense of the art, e.g. an RNA
polymerase binding site in the Jacob-Mond theory of gene expression. The promoter could additionally include one or more features to ensure or to increase expression in a suitable host. For example, the features can be conserved regions such as a Pribnow Box or a TATA box. The promoters may even contain other sequences to affect (such as to maintain, enhance, decrease) the levels of expression of the nucleotide sequence of the present invention. For example, suitable other sequences include the Shl-intron or an ADH intron. Other sequences include inducible elements - such as temperature, chemical, light or stress inducible elements.
Also, suitable elements to enhance transcription or translation may be present. An example of the latter element is the TMV 5' signal sequence (see Sleat Gene 217 [1987]
217-225; and Dawson Plant Mol. Biol. 23 [1993] 97).
SUBSTITUTE SHEET (RULE 26) Thus, in one aspect, the nucleotide sequence according to the present invention is under the control of a promoter that allows expression of the nucleotide sequence.
In this aspect, the promoter may be a cell or tissue specific promoter. If, for example, the organism is a plant then the promoter can be one that affects expression of the nucleotide sequence in any one or more of seed, stem, sprout, root and leaf tissues.
By way of example, the promoter for the nucleotide sequence of the present invention can be the a-Amy 1 promoter (otherwise known as the Arny 1 promoter, the Amy 637 promoter or the a-Amy 637 promoter) as described in PCT/EP95/02195.
IO
Alternatively. the promoter for the nucleotide sequence of the present invention can be the a-Amy 3 promoter (otherwise known as the Amy 3 promoter, the Amy 351 promoter or the a-Amy 351 promoter) as described in PCT/EP95/02196. With the Amy 351 promoter it is possible to inactivate a part of it so that the partially inactivated promoter expresses I S the nucleotide sequence in a more specific manner such as in just one specific tissue type or organ. The term "inactivated" means partial inactivation in the sense that the expression pattern of the promoter is modified but wherein the partially inactivated promoter still functions as a promoter. However, as mentioned above, the modified promoter is capable of expressing the nucleotide sequence in at least one (but not all) 20 specific tissue of the original promoter. Examples of other partial inactivation of a promoter sequence (and not just necessarily that of the Amy 351 promoter) include altering the folding pattern of the promoter sequence, or binding species to parts of the nucleotide sequence, so that a part of the nucleotide sequence is not recognised by, for example, a specific RNA polymerase. Another, and preferable, way of partially 25 inactivating the Amy 351 promoter is to truncate it to form fragments thereof. Another way would be to mutate at least a part of the sequence so that the RNA
polymerase can not bind to that pan or another part.
Another modification is to mutate the binding sites for regulatory proteins for example the 30 CreA protein known from filamentous fungi to exert carbon catabolite repression, and thus abolish the catabolite repression of the native promoter.
SUBSTITUTE SHEET (RULE 26~
The present invention therefore concerns affecting mannose-to-galactose ratios by the use of recombinant DNA techniques.
General teachings of recombinant DNA techniques may be found in Sambrook, J., Fritsch, E.F., Maniatis T. (Editors) Molecular Cloning. A laboratory manual.
Second edition. Cold Spring Harbour Laboratory Press. New York 1989.
The present invention also concerns affecting mannose-to-galactose ratios of or within a plant - such as by preparing a transgenic plant. Even though the enzyme and the nucleotide sequence of the present invention are not disclosed in EP-B-0470145 and CA
A-2006454, those two documents do provide some useful background commentary on the types of techniques that may be employed to prepare transgenic plants according to the present invention. An adaption of some of these background teachings is now included in the following commentary.
The basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material.
Several techniques exist for inserting the genetic information, the two main principles being direct introduction of the genetic information and introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).
Thus, in one aspect, the present invention relates to a vector system which carries the nucleotide sequence or construct according to the present invention and which is capable of introducing the nucleotide sequence or construct into the genome of an organism, such as a plant. The vector system may comprise one vector, but it can comprise two vectors.
In the case of two vectors, the vector system is normally referred to as a binary vector SUBSTITUTE SHEET (RULE 26) system. Binary vector systems are described in further detail in Gynheung An et al.
(1980), Binary Vectors, Plant Molecular Biology Manual A3, 1-19.
One extensively employed system for transformation of plant cells with a given promoter 5 or nucleotide sequence or construct is based on the use of a Ti plasmid from Agrobacterium tumefaciens or a Ri plasmid from Agrobacterium rhizogenes An et al.
(1986), Plant Physiol. 8I, 301-305 and Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds.: D.S. ingrams and J.P. Helgeson, 203-208.
EPIMERASE
ANTISENSE RNA
The present invention relates to a modification process.
In particular, the present invention relates to an in vivo modification process.
Galactomannans are a heterogenous group of cell wall polysaccharides consisting of a ~3-1-4 linked mannan backbone with varying numbers of a-1-6 linked galactose side chains.
The galactomannans of most significant industrial use are obtained from the endosperms of the legumes g<.Iar (Cyamopsis tetragonolobus) and locust bean (Ceratonia siliqua). These galactomannans differ in their galactose content, with guar having a galactose to mannose ratio of approximately 1:1.6, whereas the ratio for locust bean gum (LBG) is approximately 1:3.4.
The differences in galactose content have significant effects on the functional properties of guar gum and LBG. Both galactomannans form highly viscous solutions at low concentrations (1-2%) but LBG has the additional property of being able to form firm gels with other polysaccharides such as xanthan, carrageenan and agarose. LBG is extensively used by the food industry in dairy products (notably ice cream), salad dressings, sauces, low calorie products and pet foods. However, the use of LBG is restricted by the high price and irregular supply.
Therefore, large scale production of galactomannans with improved functional properties, such as a result of an increased mannose to galactose ratio (such as that similar to LBG), is desirable.
Due to the generic chemical similarity between guar gum and LBG and the much lower price on guar gum, it has been attempted in vitro to convert guar gum into a galactomannan with LBG-like properties and with a chemical composition similar to LBG.
SUBSTITUTE SHEET (RULE 26) An example of such an in vitro treatment includes the use of a-galactosidase.
In this regard, see McCleary et al 1983 and EP-A-0255153.
By using a-galactosidase purified from guar seeds, guar gum with galactose contents of 10-34% was obtained (Bulpin et al 1990). Analysis of the gelation behaviour of the modified guar gum showed that a preparation with a galactose content of 24 %
formed mixed gels with carrageenan displaying similar rheological properties as LBG.
In comparison, the galactose content of untreated guar gum was 38 % and 23 % for LBG.
However, from an industrial point of view in vitro degalactosylation of guar gum is associated with a number of problems.
First, huge amounts of a-galactosidase have to be prepared as about 40% of the galactose in the guar gum has to be removed.
Second, during incubation it is very important that no hydrolysis of the mannan backbone occurs necessitating the use of highly purified a-galactosidase preparations devoid of any trace of mannanase activity. A procedure for heterologous production of the a-galactosidase from guar seed has been published (Overbeeke et al 1986).
However, the produced a-galactosidases from the tested species were purified before investigating the action on guar gum suggesting that the mannanase problem remains to be solved.
Third, the yield of galactomannan is reduced because a 40% reduction in galactose content corresponds to approximately 15 % less modified guar gum. The released galactose may be undesirable in the final product and may have to be removed.
Fourth, there is a considerable risk for depolymerisation of the galactomannan during incubation with a-galactosidase.
SUBSTITUTE SHEET (RULE ~.~ ) Also, there is a risk for contaminating microorganisms to colonise the reaction mixture releasing endo-~i-mannanases.
Finally, water has to be removed from the reaction mixture. In addition to the cost of this process, it will also result in concentration of the buffer that may be used for obtaining optimal reaction conditions.
These examples demonstrate that the present methods for the modification of guar gum are associated with problems, some of which are associated with considerable costs.
There is therefore a need to have an improved method for the modification of guar gum.
In this regard, we have already proposed the modification of a mannose/galactose containing compound (such as guar gum) wherein the modification occurs in vivo in plants, such as guar plants, and by use of recombinant DNA techniques. In particular, we refer to PCT/EP96/05581 which was filed 2 December 1996 (the contents of which are incorporated herein by reference).
In its broadest sense, PCTIEP96/05581 relates to in vivo modification of a mannose/galactose containing compound - such as guar gum - in an organism (or part thereof) capable of synthesising that compound by a method that is not native to that organism - such as by a method that makes use of recombinant DNA techniques.
The modification may occur in relation to any one or more of the precursors of the compound (e.g. mannose and/or galactose) or in relation to the compound itself (i.e.
modification of the mannose and/or galactose units of a compound comprising same).
In particular, PCT/EP96/05581 relates to an in vivo modification process that affects, preferably increases, the mannose-to-galactose ratio of either an organism (or part thereof) capable of producing a mannose/galactose containing compound or of a mannoselgalactose containing compound thereof. This in vivo modification process is not a naturally occurring process.
SUBSTITUTE SHEET (RULE 26) Thus, with the in vivo process of PCT/EP96/05581, it is possible to alter the internal in vivo ratio of mannose to galactose within an organism and/or the ratio of mannose to galactose of a mannose/galactose compound thereof.
One of the requirements for the production of in vivo modified guar gum is the availability of a method for the introduction of suitable genes into guar. This has been accomplished to a limited extent by J~rsboe and Okkels (1994) who transferred a selectable and screenable gene used for the development of the transformation method. These authors did not report on transformation with a gene to affect the mannose to galactose ratio. This is an important point as, from a biotechnological point of view, the major obstacle for the production of in vivo modified guar gum is the lack of knowledge of galactomannan biosynthesis. Up until now, no genes or gene products which control the biosynthesis of guar gum in vivo have been isolated and characterised. However, in PCTIEP96/05581 we 1 ~ determined some of the genes or gene products which control the biosynthesis of guar gum in vivo - thus enabling us to modify guar gum in vivo.
We now provide a new process for the modification of a mannose/galactose containing compound (such as guar gum).
According to a first aspect of the present invention we provide an in vivo modification process that affects the mannose-to-galactose ratio of either an organism (or part thereof) capable of producing a mannose/galactose containing compound or of a mannose/galactose containing compound thereof, wherein the in vivo modification process comprises expressing a nucleotide sequence that has an effect on: (a) the mannose-to-galactose ratio of mannose and galactose components of a mannoselgalactose containing compound;
and/or (b) the mannose-to-galactose ratio of mannose and galactose precursors for a mannoselgalactose containing compound; and wherein the nucleotide sequence is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme.
SUBSTITUTE ShIEET (RULE 26) According to a second aspect of the present invention we provide the use of a nucleotide sequence to affect in vivo the mannose-to-galactose ratio of either an organism (or part thereof) capable of producing a mannose/galactose containing compound or of a mannose/galactose containing compound thereof, wherein the nucleotide sequence is 5 antisense to at least a part of the gene for a UDP-galactose epimerase enzyme, and wherein the nucleotide sequence has an effect on: (a) the mannose-to-galactose ratio of mannose and galactose components of a mannose/galactose containing compound;
and/or (b) the mannose-to-galactose ratio of mannose and galactose precursors for a mannose/galactose containing compound.
In a preferred embodiment, the nucleotide sequence is antisense to at least a pan of the coding sequence for a UDP-galactose epimerase enzyme.
The term "mannose/galactose containing compound" means a compound comprising at least one mannose group and at least one galactose group.
It is preferred that the mannose/galactose containing compound is gaiactomannan.
It is more preferred that the mannose/galactose containing compound is guar gum.
It is more preferred that the organism capable of producing a mannose/galactose containing compound is a guar plant and the mannose/galactose containing compound thereof is galactomannan. However, other galactomannan producing plants are encompassed such as fenugreek and Lucerne. Plants that are considered not to produce appropriate quantities of galactomannan belong to the family Solanacea and the species Nicotiana tabacum.
The term "organism (or part thereof) capable of producing a mannose/galactose containing compound" also includes any suitable organism - in particular a plant -capable of producing a mannose/galactose containing compound, such that the internal in vivo ratio of mannose to galactose of that organism is altered. The term also includes any part of an SUBSTITUTE SHEET (RULE 26) organism that is capable of producing a mannose/galactose containing compound, such that the ratio of mannose to galactose of that part is altered. The term also includes a pan when within an organism or in a live culture medium. Preferably, the part is when within an organism per se. An example of a part is seed.
The term "mannose and galactose precursors" includes mannose per se or derivatives thereof and/or galactose per se or derivatives thereof as precursors for the biosynthesis of a mannose/galactose containing compound, preferably galactomannan. In addition, the term includes precursors for mannose per se or derivatives thereof and/or galactose per se or derivatives thereof which in turn are used as precursors for the biosynthesis of a mannose/galactose containing compound, preferably galactomannan. Preferably, the term means mannose per se or derivatives thereof (such as mannose-6-phosphate or GDP-mannose) and/or galactose per se or derivatives thereof as precursors for the biosynthesis of galactomannan, preferably guar galactomannan.
Preferably the in vivo mannose-to-galactose ratio of the organism (or part thereof) or mannose/gaiactose containing compound thereof is higher than that of the guar plant or the galactomannan thereof.
More preferably the in vivo mannose-to-galactose ratio of the organism (or part thereof or mannose/galactose containing compound thereof is substantially similar to that of the locust bean or the galactomarman thereof.
Preferably the organism (or part thereof) or mannose/galactose containing compound thereof is a guar plant or the gum thereof.
The present invention also covers a mannose/galactose containing compound when prepared by the process of the present invention. This mannose/galactose containing compound will be referred to as a mannose/galactose containing compound according to the present invention.
SUBSTITUTE SHEET (RULE 26) In addition, the present invention also covers a foodstuff comprising a mannose/galactose containing compound according to the present invention.
In addition, the present invention also covers a composition - such as a foodstuff -comprising a mannose/galactose containing compound according to the present invention admixed with another polysaccharide. Preferably that other saccharide is any one or more of xanthan, carrageenan and agarose.
In addition, the present invention covers methods for preparing compositions or foodstuffs according to the present invention comprising mixing the mannose/galactose containing compound according to the present invention with another suitable ingredient.
The broad aspects of the present invention can be achieved by the use of a nucleotide sequence that is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme. UDP-galactose epimerase enzyme converts UDP-glucose to UDP-galactose which is incorporated into the galactomannan. With this strategy, expression of antisense UDP-galactose epimerase reduces the epimerase activity and thereby increases the in vivo mannose-to-galactose ratio of mannose and galactose precursors for the biosynthesis of a mannose containing compound, such as galactomannan.
A preferred aspect of the present invention relates to a construct comprising or expressing the nucleotide sequence of the present invention.
Another preferred aspect of the present invention relates to a vector comprising or expressing the construct or nucleotide sequence of the present invention.
Another preferred aspect of the present invention relates to a plasmid comprising or expressing the vector, constn:ct or nucleotide sequence of the present invention.
SUBSTITUTE SHEET (RULE 26) Another preferred aspect of the present invention relates to a transgenic organism comprising or expressing the plasmid, vector, construct or nucleotide sequence of the present invention.
Other preferred aspects of the present invention include methods of expressing or allowing expression or transforming anyone of the nucleotide sequence, the construct, the plasmid, the vector, the cell, the tissue, the organ or the organism, as well as the products thereof.
Further preferred aspects of the present invention include uses of the antisense nucleotide sequence according to the present invention for preparing or treating foodstuffs, including animal feed.
One of the key advantages of the present invention is that by using the anti-sense sequence it is possible to increase the mannose-to-galactose ratio of organisms or mannose containing compounds thereof, in particular in vivo modified guar gum.
The antisense nucleotide sequence may be used in vivo in combination with one or more other nucleotide sequences, which nucleotide sequences are preferably prepared by use of recombinant DNA techniques.
Likewise the nucleotide sequence of the present invention may be used in combination with one or more gene products to further affect the mannose-to-galactose ratio, which gene products are preferably prepared by use of recombinant DNA techniques.
Here, the gene products can be any one or more of peptides, polypeptides, proteins, enzymes and RNA. Preferably, at least one of the gene products is an enzyme that is expressed by a nucleotide sequence that is not a natural nucleotide sequence. Here, the term "a natural nucleotide sequence" means an entire nucleotide sequence that is in its natural environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its natural environment.
SU6STITUTE SHEET (RULE 26) By way of example, in some instances it is preferred that the antisense nucleotide sequence according to the present invention is used in conjunction with one or more genes encoding enzymes that are required for the biosynthesis of GDP-mannose - namely the enzyme phosphomannose isomerase (PMI) and/or the enzyme phosphomannose mucase and/or the enzyme GDP-mannose pyrophosphorylase - and/or with one or more genes encoding an a-galactosidase.
In a more preferred instance the nucleotide sequence according to the present invention is used in conjunction with a gene encoding the enzyme phosphomannose isomerase (PMI) and/or with a Gene encoding an a-aalactosidase. A preferred PMI and a-galactosidase are disclosed and discussed in PCTlEP96/0558I (the contents of which are incorporated herein by reference).
The present invention also encompasses the use of variants, homologues or fragments of the nucleotide sequence according to the present invention. Here the terms "variant" , "homologue" or "fragment" in relation to the nucleotide sequence include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence is similar to a nucleotide sequence that is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme and wherein the resultant nucleotide sequence is capable of affecting the mannose-to-galactose ratio as defined above. These terms are synonymous with allelic variations of the sequences.
The UDP-galactose epimerase enzyme - the gene sequence of which the nucleotide sequence of the present invention is antisense to - may be any suitable UDP-galactose epimerase enzyme. Preferably the UDP-galactose epimerase enzyme - the gene sequence of which the nucleotide sequence of the present invention is antisense to - is an endogenous UDP-galactose epimerase enzyme or an enzyme having a sequence similar thereto (such as at least 85 % sequence similarity, preferably at least 90%
sequence similarity, more preferably at least 95 % sequence similarity, more preferably at least 98 sequence similarity).
SUBSTITUTE SHEET (RULE 26) In accordance with a preferred embodiment of the present invention the UDP-galactose epimerase enzyme - the gene sequence of which the nucleotide sequence of the present invention is antisense to - may be or may comprise the amino acid sequence as presented in SEQ ID No. 1 or SEQ ID No. 2, or a variant, homologue or fragment thereof.
In accordance with a more preferred embodiment of the present invention the UDP-galactose epimerase enzyme - the gene sequence of which the nucleotide sequence of the present invention is antisense to - may be or may comprise the amino acid sequence as presented in SEQ ID No. 1 or SEQ ID No. 2.
In addition, and according to a further preferred embodiment of the present invention the nucleotide sequence of the present invention is antisense to the UDP-galactose epimerase enzyme coding sequence that is presented in SEQ ID No. 1 or SEQ ID No. 2, or a variant, homologue or fragment thereof.
According to a further preferred embodiment of the present invention the nucleotide sequence of the present invention is antisense to the UDP-galactose epimerase enzyme coding sequence that is presented in SEQ ID No. 1 or SEQ iD No. 2.
As indicated above, the terms "variant" , "homologue" or "fragment" in relation to the amino acid sequence for the preferred UDP-gaiactose epimerase enzyme vis-a-vis the antisense nucleotide sequence of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant enzyme has UDP-galactose epimerase activity, preferably having at least the same activity of the enzyme comprising the sequence shown as SEQ ID No. 1 or SEQ ID No. 2. In particular, the term "homologue"
covers homology with respect to structure and/or function. With respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90%o homology to an enzyme comprising the sequence shown as SEQ ID
No. 1 or SEQ ID No. ? . More preferably there is at least 95 % , more preferably at least 98 % , SUBSTITUTE SHEET (RULE 28) homology to an enzyme comprising the sequence shown as SEQ ID No. 1 or SEQ ID
No.
2.
The terms "variant", "homologue" or "fragment'' in relation to the nucleotide sequence coding for the UDP-galactose epimerase enzyme vis-a-vis the antisense nucleotide sequence of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence codes for or is capable of coding for an enzyme having UDP-galactose epimerase activity, preferably having at least the same activity of the enzyme comprising the sequence shown as SEQ ID No. 1 or SEQ ID
No.
2. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence codes for or is capable of coding for an enzyme having UDP-galactose epimerase activity. With respect to sequence homology, preferably there is at least 75 % , more preferably at least 85 % , more preferably at least 90% homology to a sequence comprising the sequence shown as SEQ ID No. 1 or SEQ
ID No. 2. More preferably there is at least 95%, more preferably at least 98%, homology to a sequence that comprises the sequence shown as SEQ ID No. 1 or SEQ ID No.
2.
The terms "variant" , "homologue" or "fragment" in relation to the antisense nucleotide sequence according to the present invention - namely a sequence that is antisense to that coding for the UDP-galactose epimerase enzyme - include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence is antisense to a sequence that codes for or is capable of coding for an enzyme having UDP-galactose epimerase activity, preferably having at least the same activity of the enzyme comprising the sequence shown as SEQ ID No. 1 or SEQ ID No. 2. In particular, the term "homologue"
covers homology with respect to structure and/or function providing the resultant nucleotide sequence is antisense to a sequence that codes for or is capable of coding for an enzyme having UDP-galactose epimerase activity. With respect to sequence homology, preferably there is at least 75 % , more preferably at least 85 % , more preferably at least 90% homology to a sequence comprising a sequence that is antisense to the sequence shown as SEQ ID No. 1 or SEQ ID No. 2. More preferably there is at least 95 %
, more SUBSTITUTE SHEET (RULE 26) preferably at least 98 % , homology to a sequence comprising a sequence that is antisense to the sequence shown as SEQ ID No. 1 or SEQ ID No. 2.
The transgenic organism of the present invention includes an organism comprising any one or more of the nucleotide sequences according to the present invention, constructs according to the present invention, vectors according to the present invention, plasmids according to the present invention, cells according to the present invention, tissues according to the present invention, or the products thereof, including combinations thereof. For example the transgenic organism can also comprise any one or more of the nucleotide sequences of the present invention under the control of one or more heterologous promoters.
In a highly preferred embodiment, the transgenic organism (or part thereof) does not comprise the combination of a promoter and the nucleotide sequence according to the present invention, wherein both the promoter and the nucleotide sequence are native to that organism (or pan thereof] and are in their natural environment.
The term "promoter" is used in the normal sense of the art, e.g. an RNA
polymerase binding site in the Jacob-Mond theory of gene expression. The promoter could additionally include one or more features to ensure or to increase expression in a suitable host. For example, the features can be conserved regions such as a Pribnow Box or a TATA box. The promoters may even contain other sequences to affect (such as to maintain, enhance, decrease) the levels of expression of the nucleotide sequence of the present invention. For example, suitable other sequences include the Shl-intron or an ADH intron. Other sequences include inducible elements - such as temperature, chemical, light or stress inducible elements.
Also, suitable elements to enhance transcription or translation may be present. An example of the latter element is the TMV 5' signal sequence (see Sleat Gene 217 [1987]
217-225; and Dawson Plant Mol. Biol. 23 [1993] 97).
SUBSTITUTE SHEET (RULE 26) Thus, in one aspect, the nucleotide sequence according to the present invention is under the control of a promoter that allows expression of the nucleotide sequence.
In this aspect, the promoter may be a cell or tissue specific promoter. If, for example, the organism is a plant then the promoter can be one that affects expression of the nucleotide sequence in any one or more of seed, stem, sprout, root and leaf tissues.
By way of example, the promoter for the nucleotide sequence of the present invention can be the a-Amy 1 promoter (otherwise known as the Arny 1 promoter, the Amy 637 promoter or the a-Amy 637 promoter) as described in PCT/EP95/02195.
IO
Alternatively. the promoter for the nucleotide sequence of the present invention can be the a-Amy 3 promoter (otherwise known as the Amy 3 promoter, the Amy 351 promoter or the a-Amy 351 promoter) as described in PCT/EP95/02196. With the Amy 351 promoter it is possible to inactivate a part of it so that the partially inactivated promoter expresses I S the nucleotide sequence in a more specific manner such as in just one specific tissue type or organ. The term "inactivated" means partial inactivation in the sense that the expression pattern of the promoter is modified but wherein the partially inactivated promoter still functions as a promoter. However, as mentioned above, the modified promoter is capable of expressing the nucleotide sequence in at least one (but not all) 20 specific tissue of the original promoter. Examples of other partial inactivation of a promoter sequence (and not just necessarily that of the Amy 351 promoter) include altering the folding pattern of the promoter sequence, or binding species to parts of the nucleotide sequence, so that a part of the nucleotide sequence is not recognised by, for example, a specific RNA polymerase. Another, and preferable, way of partially 25 inactivating the Amy 351 promoter is to truncate it to form fragments thereof. Another way would be to mutate at least a part of the sequence so that the RNA
polymerase can not bind to that pan or another part.
Another modification is to mutate the binding sites for regulatory proteins for example the 30 CreA protein known from filamentous fungi to exert carbon catabolite repression, and thus abolish the catabolite repression of the native promoter.
SUBSTITUTE SHEET (RULE 26~
The present invention therefore concerns affecting mannose-to-galactose ratios by the use of recombinant DNA techniques.
General teachings of recombinant DNA techniques may be found in Sambrook, J., Fritsch, E.F., Maniatis T. (Editors) Molecular Cloning. A laboratory manual.
Second edition. Cold Spring Harbour Laboratory Press. New York 1989.
The present invention also concerns affecting mannose-to-galactose ratios of or within a plant - such as by preparing a transgenic plant. Even though the enzyme and the nucleotide sequence of the present invention are not disclosed in EP-B-0470145 and CA
A-2006454, those two documents do provide some useful background commentary on the types of techniques that may be employed to prepare transgenic plants according to the present invention. An adaption of some of these background teachings is now included in the following commentary.
The basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material.
Several techniques exist for inserting the genetic information, the two main principles being direct introduction of the genetic information and introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).
Thus, in one aspect, the present invention relates to a vector system which carries the nucleotide sequence or construct according to the present invention and which is capable of introducing the nucleotide sequence or construct into the genome of an organism, such as a plant. The vector system may comprise one vector, but it can comprise two vectors.
In the case of two vectors, the vector system is normally referred to as a binary vector SUBSTITUTE SHEET (RULE 26) system. Binary vector systems are described in further detail in Gynheung An et al.
(1980), Binary Vectors, Plant Molecular Biology Manual A3, 1-19.
One extensively employed system for transformation of plant cells with a given promoter 5 or nucleotide sequence or construct is based on the use of a Ti plasmid from Agrobacterium tumefaciens or a Ri plasmid from Agrobacterium rhizogenes An et al.
(1986), Plant Physiol. 8I, 301-305 and Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds.: D.S. ingrams and J.P. Helgeson, 203-208.
10 Several different Ti and Ri plasmids have been constructed which are suitable for the construction of the plant or plant cell constructs described above.
The nucleotide sequence or construct of the present invention should preferably be inserted into the Ti-plasmid between the terminal sequences of the T-DNA or adjacent a T-DNA
15 sequence so as to avoid disruption of the sequences immediately surrounding the T-DNA
borders, as at least one of these regions appears to be essential for insertion of modified T-DNA into the plant genome.
As will be understood from the above explanation, if the organism is a plant, then the vector system of the present invention is preferably one which contains the sequences necessary to infect the plant {e.g. the vir region) and at least one border part of a T-DNA
sequence, the border part being located on the same vector as the genetic construct.
Furthermore, the vector system is preferably an Agrobacterium tumefaciens Ti-plasmid or an Agrobacterium rhizogenes Ri-plasmid or a derivative thereof, as these plasmids are well-known and widely employed in the construction of transgenic plants, many vector systems exist which are based on these plasmids or derivatives thereof.
In the construction of a transgenic plant the nucleotide sequence or construct of the present invention may be first constructed in a microorganism in which the vector can replicate and which is easy to manipulate before insertion into the plant. An example of a useful SUBSTITUTE SHEET (RULE 26) microorganism is E. coli, but other microorganisms having the above properties may be used. When a vector of a vector system as defined above has been constructed in E. coli, it is transferred, if necessary, into a suitable Agrobacterium strain, e.g.
Agrobacterium tumefaciens. The Ti-plasmid harbouring the nucleotide sequence or construct of the invention is thus preferably transferred into a suitable Agrobacterium strain, e.g. A.
tumefaciens, so as to obtain an Agrobacterium cell harbouring the nucleotide sequence or construct of the invention, which DNA is subsequently transferred into the plant cell to be modified.
IO As reported in CA-A-2006454, a large amount of cloning vectors are available which contain a replication system in E. coli and a marker which allows a selection of the transformed cells. The vectors contain for example pBR 322, pUC series, M13 mp series, pACYC 184 etc.
In this way, the nucleotide or construct of the present invention can be introduced into a suitable restriction position in the vector. The contained plasmid is used for the transformation in E. coli . The E. coli cells are cultivated in a suitable nutrient medium and then harvested and lysed. The plasmid is then recovered. As a method of analysis there is generally used sequence analysis, restriction analysis, electrophoresis and further biochemical-molecular biological methods. After each manipulation, the used DNA
sequence can be restricted and connected with the next DNA sequence. Each sequence can be cloned in the same or different piasmid.
After each introduction method of the construct or nucleotide sequence according to the present invention in the plants the presence and/or insertion of further DNA
sequences may be necessary. If, for example, for the transformation the Ti- or Ri-plasmid of the plant cells is used, at least the right boundary and often however the right and the left boundary of the Ti- and Ri-plasmid T-DNA, as flanking areas of the introduced genes, can be connected. The use of T-DNA for the transfornnation of plant cells has been intensively studied and is described in EP-A-120516; Hoekema, in: The Binary Plant SUBSTITUTE SHEET (RULE 26) Vector System Offset-drukkerij Kanters B.B., Alblasserdam, 1985, Chapter V;
Fraley, et al., Crit. Rev. Plant Sci., 4:1-46; and An et al., EMBO J. (1985) 4:277-284.
Direct infection of plant tissues by Agrobacterium is a simple technique which has been widely employed and which is described in Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds.: D.S. Ingrams and J.P. Helgeson, 203-208.
For further teachings on this topic see Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).
With this technique, infection of a plant may be done on a certain part or tissue of the plant, i.e. on a part of a leaf, a root, a stem or another part of the plant.
Typically, with direct infection of plant tissues by Agrobacterium carrying the nucleotide sequence of the present invention, a plant to be infected is wounded, e.g. by cutting the plant with a razor or puncturing the plant with a needle or rubbing the plant with an abrasive. The wound is then inoculated with the Agrobacterium. The inoculated plant or plant part is then grown on a suitable culture medium and allowed to develop into mature plants.
When plant cells are constructed, these cells may be grown and maintained in accordance with well-known tissue culturing methods such as by culturing the cells in a suitable culture medium supplied with the necessary growth factors such as amino acids, plant hormones, vitamins, etc.
Regeneration of the transformed cells into genetically modified plants may be accomplished using known methods for the regeneration of plants from cell or tissue cultures, for example by selecting transformed shoots using an antibiotic and by subculturing the shoots on a medium containing the appropriate nutrients, plant hormones, etc.
Further teachings on plant transformation may be found in EP-A-0449375.
SUBSTITUTE SHEET (RULE 26) Even further useful teachings on the transformation of plants can be found in Danish patent application No. 940662 (filed 10 June 1994) and/or United Kingdom patent application No. 9702592.8 (filed 7 February 1997).
Reference may even be made to Spngstad et al (1995 Plant Cell Tissue Organ Culture 40 pp 1-15} as these authors present a general overview on transgenic plant construction.
By way of example, transgenic guar plants according to the present invention can be achieved by transformation of guar cotyledonary explants by the method according to Joersbo and Okkels (PCT/DK95/00221) using Agrobacterium tumefaciens LBA4404.
The following samples were deposited in accordance with the Budapest Treaty at the recognised depositary The National Collections of Industrial and Marine Bacteria Limited (NCIMB) at 23 St. Machar Drive, Aberdeen, Scotland, United Kingdom, AB2 1RY on May 1997:
1. E. coli DHSapGEPI42. The deposit number is NCIMB 40881. NCIMB 40881 contains clone GEPI42 - which comprises SEQ ID No. 1.
2. E. coli DHSapGEPI48. The deposit number is NCIMB 40882. NCIMB 40882 contains clone GEPI48 - which comprises SEQ ID No. 2.
Thus, according to a preferred embodiment the nucleotide sequence of the present invention is antisense to the UDP-galactose epimerase enzyme coding sequence that is obtainable from deposit number NCIMB 40881 or NCIMB 40882, or is a variant, homologue or fragment thereof.
SUBSTITUTE SHEET (RULE 26) According to a more preferred embodiment the nucleotide sequence of the present invention is antisense to the UDP-galactose epimerase enzyme coding sequence that is obtainable from deposit number NCIMB 40881 or NCIMB 40882.
The present invention will now be described only by way of examples.
Cloning and partial characterization of UDP-galactose epimerase genes from guar (Cyamopsis tetragonoloba) Biochemical studies on UDP-galactose 4-epimerase {EC 5.1.3.2.) in guar have shown that even though fairly high activity of this enzyme is found, the amount of UDP-galactose epimerase protein was very small preventing preparative purification for amino acid analysis. Therefore, the cloning strategy of choice was by functional complementation in an galE- E. coli mutant.
cDNA library A cDNA expression library representing mRNA from immature guar seeds was constructed in the plasmid pcDNAII (Invitrogen Corporation) and transformed into the E.
coli strain ToplOF'. The quality of the cDNA library was controlled by purification of plasmids from a number of separate ToplOF' colonies, picked at random.
Restriction enzyme analysis revealed that all examined plasmids were recombinant.
UDP-galactose epimerase deficient E. toll strain The E. toll strain PL-2 is not able to metabolise galactose due to a defective galE- gene while the two other genes of the gal-operon, galK and gall, are intact (Buttin, J Mol Biol, 7, 164-182 (1963); Wu and Kalckar, Proc Nat Acad Sci, USA 55, 622-629 (1966).
Thus, insertion of an active UDP-galactose epimerase gene in PL-2 would allow this strain to grow on galactose.
SUBSTITUTE SHEET (RULE 26) Transformation of PL-2 and selection PL-2 cells were made competent by the method of Hanahan (Techniques for transformation of E. coli. IRL Press, Oxford (ISBN 0-947946-18-17), 109-135 (1985). A
5 titer of 5 x 106 transformed cells/p,g library plasmid was obtained.
The selection medium was essentially a minimal medium added galactose, consisting of M9 salts (Maniatis et al, Molecular cloning, a laboratory manual, Cold Spring Harbor, New York (ISBN 0-87969-136-0) (1982} and added 0.05 g/1 threonine, 0.05 gJl leucine, 10 0.05 g/I methionine, 1.0 gll of thiamin-HC1, 50 mg/1 ampicillin, 0.8 g/1 fructose, 0.9 g/1 agarose and 6 or 8 g/1 galactose. The media are hereafter called M9-ES6 (containing 6 g/i galactose} or M9-ES8 (containing 8 g/1 galactose).
Competent PL-2 cells were transformed with the guar cDNA library and cells were plated 15 onto the selective substrate M9-ES6 or M9-ESB. After two days at 37°C, colonies appeared (approx 0.1 % of the total number of transformants). A total of 48 colonies were selected.
UDP-galactose epimerase assay on selected colonies In order to establish whether the acquired ability to grow on galactose was due to the presence of UDP-galactose activity, all selected colonies were tested for UDP-galactose epimerase activity using crude extracts produced by sonication and subsequent clarification by centrifugation. The UDP-galactose epimerase assays were performed essentially according to Dey (Phytochem, 23, 729-732 (1984)). The UDP-galactose epimerase activity in extracts of PL-2 was zero (negative control) while significant levels of activity was found in DHSa (positive control), as expected. Transformed PL-2 colonies displaying high levels of UDP-galactose epimerase activity were chosen for further analysis.
SUBSTITUTE SHEET (RULE 26) Retransformation with plasmid DNA from colonies 42 and 48 Plasmids from colony 42 and colony 48 were purified and retransformed into competent PL-2 cells and plated on M9-ES6 or M9-ESB. In both retransformation experiments, a large number of colonies appeared after two days at 37°C. About ten independent colonies from each were analysed for UDP-galactose epimerase activity and all extracts contained similar high levels of UDP-galactose activity as found in the original colonies 42 and 48. This experiment demonstrates that the UDP-galactose epimerase activity detected in the PL-2 derived colonies 42 and 48 is encoded by the cDNA inserts.
DNA sequencing analysis of the inserts in colonies 42 and 48 Partial nucleotide sequences of the UDP-galactose-4-epimerase containing clones, pGEPI42 and pGEPI48, were determined using a Termo sequenase fluorescent cycle sequencing kit (Amersham) and an ALF DNA sequencer (Pharmacia).
Sequence ID No. 1 and No. 2 show partial nucleotide sequences of the inserts in colonies 42 and 48, respectively, along with the deduced amino acid sequences.
Antisense Experiments Antisense nucleotide sequences to the above-mentioned clones of interest are prepared and are used to transform guar gum by following the above-mentioned techniques.
Resultant analysis reveals that it is possible to increase the mannose-to-galactose ratio of guar gum by the insertion of one or more of those antisense sequences. Thus, the present invention is based on the surprising finding that it is possible to increase the mannose-to-galactose ratio of guar gum by the insertion of a nucleotide sequence that is an antisense nucleotide sequence.
Other modifications of the present invention will be apparent to those skilled in the art.
SUBSTITUTE SHEET (RULE 26) Bojsen et al (1993) PCT patent application WO 94/20627 Bulpin P V, Gidley M J, Jeffcoat R, Underwood D R. Development of a biotechnological process for the modification of galactomannan polymers with plant a-~alactosidase.
Carbohydr. Polymers 1990, 12:155.
Edwards M, Bulpin P V, Dea I C M, Reid J S G. Biosynthesis of legume-seed galactomannan in vitro. Planta. 1989, 178:41.
J~rsboe M and Okkles F T (1994) Transformation of guar. PCT patent application PCT/DK95/00221.
McCleary B V, Critchley P, Bulpin B V. Processing of polysaccharides. European patent application, 1983, EP-A-0 12I 960.
Maniatis T, Fritsch E F, Sambrook J (1982). Molecular cloning a laboratory manual.
Cold Spring Harbor Laboratory. Cold Spring Harbor, New York. ISBN: 0-87969-136-0.
Overbeeke N, Fellinger A J, Hughes S G. Production of guar alpha-galactosidase by hosts transformed by recombinant DNA methods. European patent application, 1986, EP-A-0 255 153.
Reid J S G, Edwards M E. Galactomannans and other cell wall storage polysaccharides in seeds. In: food polysaccharides and their application. Ed: A M Stephen, Marcel Dekker, 1995, pp 155-186.
SUBSTITUTE SHEET (RULE 26) WO 98/54335 Z~ PCT/IB98/00891 _..***.**,.*_,.;.***,.*******,.********,.,._,.,.***,.
* TRANSLATION OF A NUCLF,TC rI.CT_D S QU=NCF.
rw,.*********,r**********"e~****,.,.**,.,wr****:r Done on DNA sequence GEPI42.
Total number o~ bases is: 381.
I I I I I I
Gt?T~TTCCTGP~ATCTGAAGTGTG~-.AGP_T~G: aTP~TP.P_ii-~GG_=sACAGTGi GTGGGc~TTTG
70 80 90 100 _.0 _.0 I I i I I I
AAGGGAF?i.GAAG?.AGAAGPAGPAGATGG T G T CGTCG_'-.GG:'.TGGCGTCT GC:GG=a MCP ~ TT
M V S S R M A S G ~ T I
I I I I i I
CTGGTA.ACTGGAGGAGCTGGATTCATCGGATCTCACACGGTGGTTCAGCTTCTGP~GCP~
L V T G G A G F I G S H T V V Q L L K Q
I I I I I I
GGGTTTCACGTATCCATCATCGACP.ATCTCT=.CP_~CTCCGTCATCGACGCCGTCCATAGG
G F H V S I I D N L Y N S V I D A V H R
I I I I I I
,- T w ,- ~ w ,-., .",...., ., ..,.- = -_,-~ =,C V "' ,.
GTTCGCCTTTTGGTGvGTCCP-C i CCTCTCCr_.:... ~.C~. =C... :_ = _ C nw,..CGv~.
VRLLVG°LLSS~i:~H _ i: ciGDl I I ! I I I
CGCPnCATCCATGACCTCGACATCCTCTTCTCTLr,~ a.CCr~ LTTTG~~r; CCGTGrTCCP.A
RNIHDLDIL_ SEiTi~r D._V IQ
( I
CT T GCGGGCCCCP?.AGG T G T G
L G ? K G V
SEp ID N0. 1 SUSSTITUT~ SIi~~T' (~IULC 26) *~******************,.****~*,.*******..****,.*
'~ TF,ANSLATIOD1 OP A NUCLEIC F.CT_D SEQLT=NCE "
r,r*********w*******,r***,e**.r*****"**..w,~r****
Done on DNA sequenc a GEPI48.
Total nu;nber o~ bases is: 351.
i I I I I I
GAATTCCTTCP.P.AGCTATCCATACCGCTTACGCATTCTTCACTCCACCTTCTCTTTCTC
TCTCAGCTCCCTTCF.ATTATGTCATCCCP~=3CGGT=CTC~GTC.'-.CCWCW:.C:CCGGTTAC
I~! S S Q T V L V T G G A G Y
I I I I i I
ATCGGCAGCCACACCGTCCTTCAGCTTCTCCTCGGTGGTTTCAAGGCCGTTGTCGTTG:~C
I G S H T V L Q L L L G G ~ K A V V V D
I I ( I I I
AACCTCGATA.~TTCTTCCGr~.GACCGCCATCCACAGi~G i ~:.? ~GGr ~CTCGCCGGTA_n.ATTC
N L D N S S E T A I H R V :~ E L A G K r 250 260 270 2°0 290 300 I I I I I I
GCCGGT= ~TCTCTCCTTTC?_CF=_GTTAG."-_CC'='TCGGG =:.:.GAG=."'GCGCTGG??_.:~.~hTT
A G N L S F i: K L D ~ .. D ~. ~ r L
I I I I I
TTTTCTTCCACAA.Z?GTTTGATT_CTGTCATACATTTTG~,TGG ~CTGP..r"-xiGCA
F S S T K F D S V I H r .. G i, K A
SEQ ID N0. 2 SU~~'~I~'tl~'~ ~Ir~~I" (~llL~ ~~~
The nucleotide sequence or construct of the present invention should preferably be inserted into the Ti-plasmid between the terminal sequences of the T-DNA or adjacent a T-DNA
15 sequence so as to avoid disruption of the sequences immediately surrounding the T-DNA
borders, as at least one of these regions appears to be essential for insertion of modified T-DNA into the plant genome.
As will be understood from the above explanation, if the organism is a plant, then the vector system of the present invention is preferably one which contains the sequences necessary to infect the plant {e.g. the vir region) and at least one border part of a T-DNA
sequence, the border part being located on the same vector as the genetic construct.
Furthermore, the vector system is preferably an Agrobacterium tumefaciens Ti-plasmid or an Agrobacterium rhizogenes Ri-plasmid or a derivative thereof, as these plasmids are well-known and widely employed in the construction of transgenic plants, many vector systems exist which are based on these plasmids or derivatives thereof.
In the construction of a transgenic plant the nucleotide sequence or construct of the present invention may be first constructed in a microorganism in which the vector can replicate and which is easy to manipulate before insertion into the plant. An example of a useful SUBSTITUTE SHEET (RULE 26) microorganism is E. coli, but other microorganisms having the above properties may be used. When a vector of a vector system as defined above has been constructed in E. coli, it is transferred, if necessary, into a suitable Agrobacterium strain, e.g.
Agrobacterium tumefaciens. The Ti-plasmid harbouring the nucleotide sequence or construct of the invention is thus preferably transferred into a suitable Agrobacterium strain, e.g. A.
tumefaciens, so as to obtain an Agrobacterium cell harbouring the nucleotide sequence or construct of the invention, which DNA is subsequently transferred into the plant cell to be modified.
IO As reported in CA-A-2006454, a large amount of cloning vectors are available which contain a replication system in E. coli and a marker which allows a selection of the transformed cells. The vectors contain for example pBR 322, pUC series, M13 mp series, pACYC 184 etc.
In this way, the nucleotide or construct of the present invention can be introduced into a suitable restriction position in the vector. The contained plasmid is used for the transformation in E. coli . The E. coli cells are cultivated in a suitable nutrient medium and then harvested and lysed. The plasmid is then recovered. As a method of analysis there is generally used sequence analysis, restriction analysis, electrophoresis and further biochemical-molecular biological methods. After each manipulation, the used DNA
sequence can be restricted and connected with the next DNA sequence. Each sequence can be cloned in the same or different piasmid.
After each introduction method of the construct or nucleotide sequence according to the present invention in the plants the presence and/or insertion of further DNA
sequences may be necessary. If, for example, for the transformation the Ti- or Ri-plasmid of the plant cells is used, at least the right boundary and often however the right and the left boundary of the Ti- and Ri-plasmid T-DNA, as flanking areas of the introduced genes, can be connected. The use of T-DNA for the transfornnation of plant cells has been intensively studied and is described in EP-A-120516; Hoekema, in: The Binary Plant SUBSTITUTE SHEET (RULE 26) Vector System Offset-drukkerij Kanters B.B., Alblasserdam, 1985, Chapter V;
Fraley, et al., Crit. Rev. Plant Sci., 4:1-46; and An et al., EMBO J. (1985) 4:277-284.
Direct infection of plant tissues by Agrobacterium is a simple technique which has been widely employed and which is described in Butcher D.N. et al. (1980), Tissue Culture Methods for Plant Pathologists, eds.: D.S. Ingrams and J.P. Helgeson, 203-208.
For further teachings on this topic see Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).
With this technique, infection of a plant may be done on a certain part or tissue of the plant, i.e. on a part of a leaf, a root, a stem or another part of the plant.
Typically, with direct infection of plant tissues by Agrobacterium carrying the nucleotide sequence of the present invention, a plant to be infected is wounded, e.g. by cutting the plant with a razor or puncturing the plant with a needle or rubbing the plant with an abrasive. The wound is then inoculated with the Agrobacterium. The inoculated plant or plant part is then grown on a suitable culture medium and allowed to develop into mature plants.
When plant cells are constructed, these cells may be grown and maintained in accordance with well-known tissue culturing methods such as by culturing the cells in a suitable culture medium supplied with the necessary growth factors such as amino acids, plant hormones, vitamins, etc.
Regeneration of the transformed cells into genetically modified plants may be accomplished using known methods for the regeneration of plants from cell or tissue cultures, for example by selecting transformed shoots using an antibiotic and by subculturing the shoots on a medium containing the appropriate nutrients, plant hormones, etc.
Further teachings on plant transformation may be found in EP-A-0449375.
SUBSTITUTE SHEET (RULE 26) Even further useful teachings on the transformation of plants can be found in Danish patent application No. 940662 (filed 10 June 1994) and/or United Kingdom patent application No. 9702592.8 (filed 7 February 1997).
Reference may even be made to Spngstad et al (1995 Plant Cell Tissue Organ Culture 40 pp 1-15} as these authors present a general overview on transgenic plant construction.
By way of example, transgenic guar plants according to the present invention can be achieved by transformation of guar cotyledonary explants by the method according to Joersbo and Okkels (PCT/DK95/00221) using Agrobacterium tumefaciens LBA4404.
The following samples were deposited in accordance with the Budapest Treaty at the recognised depositary The National Collections of Industrial and Marine Bacteria Limited (NCIMB) at 23 St. Machar Drive, Aberdeen, Scotland, United Kingdom, AB2 1RY on May 1997:
1. E. coli DHSapGEPI42. The deposit number is NCIMB 40881. NCIMB 40881 contains clone GEPI42 - which comprises SEQ ID No. 1.
2. E. coli DHSapGEPI48. The deposit number is NCIMB 40882. NCIMB 40882 contains clone GEPI48 - which comprises SEQ ID No. 2.
Thus, according to a preferred embodiment the nucleotide sequence of the present invention is antisense to the UDP-galactose epimerase enzyme coding sequence that is obtainable from deposit number NCIMB 40881 or NCIMB 40882, or is a variant, homologue or fragment thereof.
SUBSTITUTE SHEET (RULE 26) According to a more preferred embodiment the nucleotide sequence of the present invention is antisense to the UDP-galactose epimerase enzyme coding sequence that is obtainable from deposit number NCIMB 40881 or NCIMB 40882.
The present invention will now be described only by way of examples.
Cloning and partial characterization of UDP-galactose epimerase genes from guar (Cyamopsis tetragonoloba) Biochemical studies on UDP-galactose 4-epimerase {EC 5.1.3.2.) in guar have shown that even though fairly high activity of this enzyme is found, the amount of UDP-galactose epimerase protein was very small preventing preparative purification for amino acid analysis. Therefore, the cloning strategy of choice was by functional complementation in an galE- E. coli mutant.
cDNA library A cDNA expression library representing mRNA from immature guar seeds was constructed in the plasmid pcDNAII (Invitrogen Corporation) and transformed into the E.
coli strain ToplOF'. The quality of the cDNA library was controlled by purification of plasmids from a number of separate ToplOF' colonies, picked at random.
Restriction enzyme analysis revealed that all examined plasmids were recombinant.
UDP-galactose epimerase deficient E. toll strain The E. toll strain PL-2 is not able to metabolise galactose due to a defective galE- gene while the two other genes of the gal-operon, galK and gall, are intact (Buttin, J Mol Biol, 7, 164-182 (1963); Wu and Kalckar, Proc Nat Acad Sci, USA 55, 622-629 (1966).
Thus, insertion of an active UDP-galactose epimerase gene in PL-2 would allow this strain to grow on galactose.
SUBSTITUTE SHEET (RULE 26) Transformation of PL-2 and selection PL-2 cells were made competent by the method of Hanahan (Techniques for transformation of E. coli. IRL Press, Oxford (ISBN 0-947946-18-17), 109-135 (1985). A
5 titer of 5 x 106 transformed cells/p,g library plasmid was obtained.
The selection medium was essentially a minimal medium added galactose, consisting of M9 salts (Maniatis et al, Molecular cloning, a laboratory manual, Cold Spring Harbor, New York (ISBN 0-87969-136-0) (1982} and added 0.05 g/1 threonine, 0.05 gJl leucine, 10 0.05 g/I methionine, 1.0 gll of thiamin-HC1, 50 mg/1 ampicillin, 0.8 g/1 fructose, 0.9 g/1 agarose and 6 or 8 g/1 galactose. The media are hereafter called M9-ES6 (containing 6 g/i galactose} or M9-ES8 (containing 8 g/1 galactose).
Competent PL-2 cells were transformed with the guar cDNA library and cells were plated 15 onto the selective substrate M9-ES6 or M9-ESB. After two days at 37°C, colonies appeared (approx 0.1 % of the total number of transformants). A total of 48 colonies were selected.
UDP-galactose epimerase assay on selected colonies In order to establish whether the acquired ability to grow on galactose was due to the presence of UDP-galactose activity, all selected colonies were tested for UDP-galactose epimerase activity using crude extracts produced by sonication and subsequent clarification by centrifugation. The UDP-galactose epimerase assays were performed essentially according to Dey (Phytochem, 23, 729-732 (1984)). The UDP-galactose epimerase activity in extracts of PL-2 was zero (negative control) while significant levels of activity was found in DHSa (positive control), as expected. Transformed PL-2 colonies displaying high levels of UDP-galactose epimerase activity were chosen for further analysis.
SUBSTITUTE SHEET (RULE 26) Retransformation with plasmid DNA from colonies 42 and 48 Plasmids from colony 42 and colony 48 were purified and retransformed into competent PL-2 cells and plated on M9-ES6 or M9-ESB. In both retransformation experiments, a large number of colonies appeared after two days at 37°C. About ten independent colonies from each were analysed for UDP-galactose epimerase activity and all extracts contained similar high levels of UDP-galactose activity as found in the original colonies 42 and 48. This experiment demonstrates that the UDP-galactose epimerase activity detected in the PL-2 derived colonies 42 and 48 is encoded by the cDNA inserts.
DNA sequencing analysis of the inserts in colonies 42 and 48 Partial nucleotide sequences of the UDP-galactose-4-epimerase containing clones, pGEPI42 and pGEPI48, were determined using a Termo sequenase fluorescent cycle sequencing kit (Amersham) and an ALF DNA sequencer (Pharmacia).
Sequence ID No. 1 and No. 2 show partial nucleotide sequences of the inserts in colonies 42 and 48, respectively, along with the deduced amino acid sequences.
Antisense Experiments Antisense nucleotide sequences to the above-mentioned clones of interest are prepared and are used to transform guar gum by following the above-mentioned techniques.
Resultant analysis reveals that it is possible to increase the mannose-to-galactose ratio of guar gum by the insertion of one or more of those antisense sequences. Thus, the present invention is based on the surprising finding that it is possible to increase the mannose-to-galactose ratio of guar gum by the insertion of a nucleotide sequence that is an antisense nucleotide sequence.
Other modifications of the present invention will be apparent to those skilled in the art.
SUBSTITUTE SHEET (RULE 26) Bojsen et al (1993) PCT patent application WO 94/20627 Bulpin P V, Gidley M J, Jeffcoat R, Underwood D R. Development of a biotechnological process for the modification of galactomannan polymers with plant a-~alactosidase.
Carbohydr. Polymers 1990, 12:155.
Edwards M, Bulpin P V, Dea I C M, Reid J S G. Biosynthesis of legume-seed galactomannan in vitro. Planta. 1989, 178:41.
J~rsboe M and Okkles F T (1994) Transformation of guar. PCT patent application PCT/DK95/00221.
McCleary B V, Critchley P, Bulpin B V. Processing of polysaccharides. European patent application, 1983, EP-A-0 12I 960.
Maniatis T, Fritsch E F, Sambrook J (1982). Molecular cloning a laboratory manual.
Cold Spring Harbor Laboratory. Cold Spring Harbor, New York. ISBN: 0-87969-136-0.
Overbeeke N, Fellinger A J, Hughes S G. Production of guar alpha-galactosidase by hosts transformed by recombinant DNA methods. European patent application, 1986, EP-A-0 255 153.
Reid J S G, Edwards M E. Galactomannans and other cell wall storage polysaccharides in seeds. In: food polysaccharides and their application. Ed: A M Stephen, Marcel Dekker, 1995, pp 155-186.
SUBSTITUTE SHEET (RULE 26) WO 98/54335 Z~ PCT/IB98/00891 _..***.**,.*_,.;.***,.*******,.********,.,._,.,.***,.
* TRANSLATION OF A NUCLF,TC rI.CT_D S QU=NCF.
rw,.*********,r**********"e~****,.,.**,.,wr****:r Done on DNA sequence GEPI42.
Total number o~ bases is: 381.
I I I I I I
Gt?T~TTCCTGP~ATCTGAAGTGTG~-.AGP_T~G: aTP~TP.P_ii-~GG_=sACAGTGi GTGGGc~TTTG
70 80 90 100 _.0 _.0 I I i I I I
AAGGGAF?i.GAAG?.AGAAGPAGPAGATGG T G T CGTCG_'-.GG:'.TGGCGTCT GC:GG=a MCP ~ TT
M V S S R M A S G ~ T I
I I I I i I
CTGGTA.ACTGGAGGAGCTGGATTCATCGGATCTCACACGGTGGTTCAGCTTCTGP~GCP~
L V T G G A G F I G S H T V V Q L L K Q
I I I I I I
GGGTTTCACGTATCCATCATCGACP.ATCTCT=.CP_~CTCCGTCATCGACGCCGTCCATAGG
G F H V S I I D N L Y N S V I D A V H R
I I I I I I
,- T w ,- ~ w ,-., .",...., ., ..,.- = -_,-~ =,C V "' ,.
GTTCGCCTTTTGGTGvGTCCP-C i CCTCTCCr_.:... ~.C~. =C... :_ = _ C nw,..CGv~.
VRLLVG°LLSS~i:~H _ i: ciGDl I I ! I I I
CGCPnCATCCATGACCTCGACATCCTCTTCTCTLr,~ a.CCr~ LTTTG~~r; CCGTGrTCCP.A
RNIHDLDIL_ SEiTi~r D._V IQ
( I
CT T GCGGGCCCCP?.AGG T G T G
L G ? K G V
SEp ID N0. 1 SUSSTITUT~ SIi~~T' (~IULC 26) *~******************,.****~*,.*******..****,.*
'~ TF,ANSLATIOD1 OP A NUCLEIC F.CT_D SEQLT=NCE "
r,r*********w*******,r***,e**.r*****"**..w,~r****
Done on DNA sequenc a GEPI48.
Total nu;nber o~ bases is: 351.
i I I I I I
GAATTCCTTCP.P.AGCTATCCATACCGCTTACGCATTCTTCACTCCACCTTCTCTTTCTC
TCTCAGCTCCCTTCF.ATTATGTCATCCCP~=3CGGT=CTC~GTC.'-.CCWCW:.C:CCGGTTAC
I~! S S Q T V L V T G G A G Y
I I I I i I
ATCGGCAGCCACACCGTCCTTCAGCTTCTCCTCGGTGGTTTCAAGGCCGTTGTCGTTG:~C
I G S H T V L Q L L L G G ~ K A V V V D
I I ( I I I
AACCTCGATA.~TTCTTCCGr~.GACCGCCATCCACAGi~G i ~:.? ~GGr ~CTCGCCGGTA_n.ATTC
N L D N S S E T A I H R V :~ E L A G K r 250 260 270 2°0 290 300 I I I I I I
GCCGGT= ~TCTCTCCTTTC?_CF=_GTTAG."-_CC'='TCGGG =:.:.GAG=."'GCGCTGG??_.:~.~hTT
A G N L S F i: K L D ~ .. D ~. ~ r L
I I I I I
TTTTCTTCCACAA.Z?GTTTGATT_CTGTCATACATTTTG~,TGG ~CTGP..r"-xiGCA
F S S T K F D S V I H r .. G i, K A
SEQ ID N0. 2 SU~~'~I~'tl~'~ ~Ir~~I" (~llL~ ~~~
Claims (18)
1. An in vivo modification process that affects the mannose-to-galactose ratio of either an organism (or part thereof) capable of producing a mannose/galactose containing compound or of a mannose/galactose containing compound thereof, wherein the in vivo modification process comprises expressing a nucleotide sequence that has an effect on:
(a) the mannose-to-galactose ratio of mannose and galactose components of a mannose/galactose containing compound; and/or (b) the mannose-to-galactose ratio of mannose and galactose precursors for a mannose/galactose containing compound;
wherein the nucleotide sequence is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme.
(a) the mannose-to-galactose ratio of mannose and galactose components of a mannose/galactose containing compound; and/or (b) the mannose-to-galactose ratio of mannose and galactose precursors for a mannose/galactose containing compound;
wherein the nucleotide sequence is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme.
2. Use of a nucleotide sequence to affect in vivo the mannose-to-galactose ratio of either an organism (or part thereof) capable of producing a mannose/galactose containing compound or of a mannose/galactose containing compound thereof, wherein the nucleotide sequence is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme, and wherein the nucleotide sequence has an effect on:
(a) the mannose-to-galactose ratio of mannose and galactose components of a mannose/galactose containing compound; and/or (b) the mannose-to-galactose ratio of mannose and galactose precursors for a mannoselgalactose containing compound.
(a) the mannose-to-galactose ratio of mannose and galactose components of a mannose/galactose containing compound; and/or (b) the mannose-to-galactose ratio of mannose and galactose precursors for a mannoselgalactose containing compound.
3. The invention according to claim 1 or claim 2 wherein the mannose/galactose containing compound is galactomannan.
4. The invention according to any one of claims 1 to 3 wherein the organism capable of producing a mannose/galactose containing compound is a guar plant.
5. The invention according to any one of claims 1 to 4 wherein the in vivo mannose-to-galactose ratio of the organism (or pan thereof) or mannose/galactose containing compound thereof is higher than that of the guar plant or the galactomannan thereof.
6. The invention according to any one of claims 1 to 5 wherein the in vivo mannose-to-galactose ratio of the organism (or part thereof) or mannose/galactose containing compound thereof is substantially similar to that of the locust bean or the galactomannan thereof.
7. A construct comprising a nucleotide sequence that is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme.
8. A vector comprising a nucleotide sequence that is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme.
9. A plasmid comprising a nucleotide sequence that is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme.
10. A transgenic organism (or part thereof) comprising a nucleotide sequence that is antisense to at least a part of the gene for a UDP-galactose epimerase enzyme.
11. A transgenic organism (or part thereof) according to claim 10 wherein the organism is a guar plant.
12. The invention according to any of one of the preceding claims wherein the nucleotide sequence is antisense to at least a part of the coding sequence for a UDP-galactose epimerase enzyme.
13. A mannose/galactose containing compound when prepared by the process of claim 1 or any claim dependent thereon.
14. A foodstuff comprising a mannose/galactose containing compound according to claim 13.
15. A composition comprising a mannose/galactose containing compound according to claim 13 admixed with another polysaccharide.
16. A composition comprising a mannose/galactose containing compound according to claim 13 admixed with any one or more of xanthan, carrageenan and agarose.
17. A method for preparing a composition or a foodstuff comprising mixing the mannose/galactose containing compound according to claim 13 with another suitable ingredient.
18. A process substantially as described herein.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9710990.4A GB9710990D0 (en) | 1997-05-28 | 1997-05-28 | Modification process |
| GB9710990.4 | 1997-05-28 | ||
| PCT/IB1998/000891 WO1998054335A1 (en) | 1997-05-28 | 1998-05-27 | In vivo modification of galactomannans in guar by expression of udp-galactose epimerase antisense rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2291449A1 true CA2291449A1 (en) | 1998-12-03 |
Family
ID=10813167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002291449A Abandoned CA2291449A1 (en) | 1997-05-28 | 1998-05-27 | In vivo modification of galactomannans in guar by expression of udp-galactose epimerase antisense rna |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0983369A1 (en) |
| JP (1) | JP2002500515A (en) |
| KR (1) | KR20010012962A (en) |
| CN (1) | CN1264428A (en) |
| AU (1) | AU733483B2 (en) |
| BR (1) | BR9809493A (en) |
| CA (1) | CA2291449A1 (en) |
| GB (2) | GB9710990D0 (en) |
| NZ (1) | NZ500951A (en) |
| WO (1) | WO1998054335A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9710990D0 (en) * | 1997-05-28 | 1997-07-23 | Danisco | Modification process |
| ITPD980169A1 (en) | 1998-07-06 | 2000-01-06 | Fidia Advanced Biopolymers Srl | AMIDES OF HYALURONIC ACID AND ITS DERIVATIVES AND PROCESS FOR THEIR PREPARATION. |
| CA2716429A1 (en) * | 1999-02-10 | 2000-08-17 | E. I. Du Pont De Nemours And Company | Udp-glucose modifiers |
| US6992236B1 (en) | 1999-02-10 | 2006-01-31 | E. I. Du Pont De Nemours And Company | Plant UDP-glucose epimerases |
| GB9914210D0 (en) | 1999-06-17 | 1999-08-18 | Danisco | Promoter |
| AU2003290793A1 (en) | 2002-11-14 | 2004-06-15 | Pioneer Hi-Bred International, Inc. | Genes for galactomannan production in plants and methods of use |
| ITPD20050056A1 (en) | 2005-03-02 | 2006-09-03 | Fidia Farmaceutici | AMIDID DERIVATIVES OF HYALURONIC ACID IN OSTEOARTROSI |
| US7585818B2 (en) | 2005-05-10 | 2009-09-08 | Halliburton Energy Services, Inc. | Nonnatural galactomannans and methods of use |
| WO2008112170A1 (en) | 2007-03-09 | 2008-09-18 | Corning Incorporated | Three dimensional gum matrices for cell culture, manufacturing methods and methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK198089D0 (en) * | 1989-04-24 | 1989-04-24 | Danske Spritfabrikker | DNA MATERIALS AND USE THEREOF |
| GB9524752D0 (en) * | 1995-12-04 | 1996-02-07 | Danisco | Modification process |
| GB9710990D0 (en) * | 1997-05-28 | 1997-07-23 | Danisco | Modification process |
-
1997
- 1997-05-28 GB GBGB9710990.4A patent/GB9710990D0/en active Pending
-
1998
- 1998-05-27 GB GB9927197A patent/GB2342920B/en not_active Expired - Fee Related
- 1998-05-27 CN CN98807406A patent/CN1264428A/en active Pending
- 1998-05-27 AU AU74463/98A patent/AU733483B2/en not_active Ceased
- 1998-05-27 BR BR9809493-9A patent/BR9809493A/en not_active IP Right Cessation
- 1998-05-27 WO PCT/IB1998/000891 patent/WO1998054335A1/en not_active Application Discontinuation
- 1998-05-27 EP EP98921695A patent/EP0983369A1/en not_active Withdrawn
- 1998-05-27 CA CA002291449A patent/CA2291449A1/en not_active Abandoned
- 1998-05-27 KR KR1019997010932A patent/KR20010012962A/en not_active Application Discontinuation
- 1998-05-27 NZ NZ500951A patent/NZ500951A/en unknown
- 1998-05-27 JP JP50042399A patent/JP2002500515A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU7446398A (en) | 1998-12-30 |
| GB9710990D0 (en) | 1997-07-23 |
| GB9927197D0 (en) | 2000-01-12 |
| GB2342920B (en) | 2001-08-15 |
| WO1998054335A1 (en) | 1998-12-03 |
| GB2342920A (en) | 2000-04-26 |
| NZ500951A (en) | 2001-09-28 |
| CN1264428A (en) | 2000-08-23 |
| AU733483B2 (en) | 2001-05-17 |
| EP0983369A1 (en) | 2000-03-08 |
| KR20010012962A (en) | 2001-02-26 |
| BR9809493A (en) | 2000-06-20 |
| JP2002500515A (en) | 2002-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69836267T2 (en) | NUCLEIC ACIDS FROM THE ARTICHOKE (CYNARA SCOLYMUS), WHICH CODE FOR AN ENZYME WITH FRUCTOSYL POLYMERASE ACTIVITY | |
| CA2624973C (en) | Production of hyaluronan from plants transgenic for hyaluronan synthase, gfat and udp-glucose dehydrogenase | |
| AU709798B2 (en) | Inhibition of gene expression | |
| JP2002510961A (en) | Plant cellulose synthase and promoter sequence | |
| JPH08507923A (en) | DNA, DNA constructs, cells and plants derived therefrom | |
| CA2280230A1 (en) | Antisense intron inhibition of starch branching enzyme expression | |
| KR19980702463A (en) | Cryogenic promoter arrangement | |
| WO1997004113A2 (en) | Inhibition of gene expression | |
| HU226140B1 (en) | Dna molecules that code for enzymes involved in strach synthesis, vectors, bacteria, transgenic plant cells and plants containing said molecules | |
| MXPA98000499A (en) | Inhibition of the expression of ge | |
| MXPA98000500A (en) | Inhibition of the expression of ge | |
| CA2136828A1 (en) | Dna sequences and plasmids for the preparation of plants with changed sucrose concentration | |
| GB2360521A (en) | Genetic modification of starch in plants | |
| AU733483B2 (en) | In vivo modification of galactomannans in guar by expression of UDP-galactose epimerase antisense RNA | |
| AU1193997A (en) | Modification process | |
| JP2002527056A (en) | Materials and methods for modification of plant cell wall polysaccharides | |
| AU778179B2 (en) | Gibberellin 3 beta-hydroxylase genes of rice and uses thereof | |
| JP3538428B2 (en) | Plant promoter and gene expression method using the promoter | |
| CN116640195A (en) | Citrus CsPIF4 gene, protein coded by same and application thereof | |
| CA2280210A1 (en) | Sense intron inhibition of starch branching enzyme expression | |
| CN115960855A (en) | Application of SlPRMT5 gene and protein thereof in regulation and control of tomato fruit ripening | |
| US7253335B2 (en) | Fructan biosynthetic enzymes | |
| US5569829A (en) | Transformed tomato plants | |
| CN101277610B (en) | Improved methods and means for producing hyaluronan | |
| WO1993014212A1 (en) | Transgenic plants with increased solids content |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |